Interferon-γ ||| S:0 E:12 ||| NNP
/ ||| S:12 E:13 ||| NNP
CCR5  ||| S:13 E:18 ||| NNP
expression  ||| S:18 E:29 ||| NN
in  ||| S:29 E:32 ||| IN
invariant  ||| S:32 E:42 ||| JJ
natural  ||| S:42 E:50 ||| JJ
killer  ||| S:50 E:57 ||| NN
T  ||| S:57 E:59 ||| NN
cells  ||| S:59 E:65 ||| NNS
and  ||| S:65 E:69 ||| CC
CCL5  ||| S:69 E:74 ||| CD
expression  ||| S:74 E:85 ||| NN
in  ||| S:85 E:88 ||| IN
capillary  ||| S:88 E:98 ||| JJ
veins  ||| S:98 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
dermal  ||| S:107 E:114 ||| JJ
papillae  ||| S:114 E:123 ||| JJ
correlate  ||| S:123 E:133 ||| NN
with  ||| S:133 E:138 ||| IN
development  ||| S:138 E:150 ||| NN
of  ||| S:150 E:153 ||| IN
psoriasis  ||| S:153 E:163 ||| NNS
vulgaris  ||| S:163 E:172 ||| VBP
There  ||| S:172 E:178 ||| EX
have  ||| S:178 E:183 ||| VBP
been  ||| S:183 E:188 ||| VBN
extensive  ||| S:188 E:198 ||| JJ
studies  ||| S:198 E:206 ||| NNS
regarding  ||| S:206 E:216 ||| VBG
which  ||| S:216 E:222 ||| WDT
types  ||| S:222 E:228 ||| NNS
of  ||| S:228 E:231 ||| IN
T  ||| S:231 E:233 ||| NN
lymphocytes  ||| S:233 E:245 ||| NNS
are  ||| S:245 E:249 ||| VBP
involved  ||| S:249 E:258 ||| VBN
in  ||| S:258 E:261 ||| IN
psoriasis  ||| S:261 E:271 ||| JJ
vulgaris  ||| S:271 E:280 ||| NNS
( ||| S:280 E:281 ||| -LRB-
PV ||| S:281 E:283 ||| NNP
) ||| S:283 E:284 ||| -RRB-
.  ||| S:284 E:286 ||| .
However ||| S:286 E:293 ||| RB
,  ||| S:293 E:295 ||| ,
it  ||| S:295 E:298 ||| PRP
has  ||| S:298 E:302 ||| VBZ
remained  ||| S:302 E:311 ||| VBN
unclear  ||| S:311 E:319 ||| NNS
which  ||| S:319 E:325 ||| WDT
types  ||| S:325 E:331 ||| NNS
of  ||| S:331 E:334 ||| IN
T  ||| S:334 E:336 ||| NN
lymphocytes  ||| S:336 E:348 ||| NNS
might  ||| S:348 E:354 ||| MD
directly  ||| S:354 E:363 ||| RB
contribute  ||| S:363 E:374 ||| VB
to  ||| S:374 E:377 ||| TO
psoriasiform  ||| S:377 E:390 ||| VB
epidermal  ||| S:390 E:400 ||| NNS
and  ||| S:400 E:404 ||| CC
vascular  ||| S:404 E:413 ||| JJ
hyperplasia ||| S:413 E:424 ||| NN
.  ||| S:424 E:426 ||| .
To  ||| S:426 E:429 ||| TO
understand  ||| S:429 E:440 ||| VB
the  ||| S:440 E:444 ||| DT
role  ||| S:444 E:449 ||| NN
of  ||| S:449 E:452 ||| IN
T-cell  ||| S:452 E:459 ||| JJ
receptor  ||| S:459 E:468 ||| NN
( ||| S:468 E:469 ||| -LRB-
TCR ||| S:469 E:472 ||| NNP
) ||| S:472 E:473 ||| -RRB-
Vα24+  ||| S:473 E:479 ||| FW
invariant  ||| S:479 E:489 ||| FW
natural  ||| S:489 E:497 ||| FW
killer  ||| S:497 E:504 ||| FW
( ||| S:504 E:505 ||| -LRB-
iNK ||| S:505 E:508 ||| NNP
) ||| S:508 E:509 ||| -RRB-
T  ||| S:509 E:511 ||| NN
cells  ||| S:511 E:517 ||| NNS
in  ||| S:517 E:520 ||| IN
the  ||| S:520 E:524 ||| DT
development  ||| S:524 E:536 ||| NN
of  ||| S:536 E:539 ||| IN
PV ||| S:539 E:541 ||| NNP
.  ||| S:541 E:543 ||| .
Seventeen  ||| S:543 E:553 ||| JJ
patients  ||| S:553 E:562 ||| NNS
were  ||| S:562 E:567 ||| VBD
enrolled  ||| S:567 E:576 ||| VBN
in  ||| S:576 E:579 ||| IN
this  ||| S:579 E:584 ||| DT
study ||| S:584 E:589 ||| NN
.  ||| S:589 E:591 ||| .
Using  ||| S:591 E:597 ||| VBG
biopsy  ||| S:597 E:604 ||| JJ
samples  ||| S:604 E:612 ||| NNS
of  ||| S:612 E:615 ||| IN
PV  ||| S:615 E:618 ||| NNP
plaques ||| S:618 E:625 ||| NN
,  ||| S:625 E:627 ||| ,
TCRVα24 ||| S:627 E:634 ||| NNP
( ||| S:634 E:635 ||| -LRB-
+ ||| S:635 E:636 ||| NNP
)  ||| S:636 E:638 ||| -RRB-
iNKT  ||| S:638 E:643 ||| JJ
cells  ||| S:643 E:649 ||| NNS
were  ||| S:649 E:654 ||| VBD
investigated  ||| S:654 E:667 ||| VBN
regarding  ||| S:667 E:677 ||| VBG
their  ||| S:677 E:683 ||| PRP$
cytokine  ||| S:683 E:692 ||| JJ
production  ||| S:692 E:703 ||| NN
to  ||| S:703 E:706 ||| TO
understand  ||| S:706 E:717 ||| VB
their  ||| S:717 E:723 ||| PRP$
roles  ||| S:723 E:729 ||| NNS
in  ||| S:729 E:732 ||| IN
development  ||| S:732 E:744 ||| NN
of  ||| S:744 E:747 ||| IN
disease ||| S:747 E:754 ||| NN
.  ||| S:754 E:756 ||| .
The  ||| S:756 E:760 ||| DT
number  ||| S:760 E:767 ||| NN
of  ||| S:767 E:770 ||| IN
interferon  ||| S:770 E:781 ||| NNS
( ||| S:781 E:782 ||| -LRB-
IFN ||| S:782 E:785 ||| NNP
) ||| S:785 E:786 ||| -RRB-
-γ+  ||| S:786 E:790 ||| CD
iNKT  ||| S:790 E:795 ||| JJ
cells  ||| S:795 E:801 ||| NNS
correlated  ||| S:801 E:812 ||| VBN
with  ||| S:812 E:817 ||| IN
the  ||| S:817 E:821 ||| DT
length  ||| S:821 E:828 ||| NN
of  ||| S:828 E:831 ||| IN
the  ||| S:831 E:835 ||| DT
psoriasiform  ||| S:835 E:848 ||| FW
hyperplasia  ||| S:848 E:860 ||| FW
rete  ||| S:860 E:865 ||| FW
ridge  ||| S:865 E:871 ||| FW
and  ||| S:871 E:875 ||| CC
the  ||| S:875 E:879 ||| DT
Psoriasis  ||| S:879 E:889 ||| NNP
Area  ||| S:889 E:894 ||| NNP
and  ||| S:894 E:898 ||| CC
Severity  ||| S:898 E:907 ||| NNP
Index ||| S:907 E:912 ||| NNP
.  ||| S:912 E:914 ||| .
IFN-γ+  ||| S:914 E:921 ||| NNP
iNKT  ||| S:921 E:926 ||| JJ
cells  ||| S:926 E:932 ||| NNS
in  ||| S:932 E:935 ||| IN
psoriatic  ||| S:935 E:945 ||| JJ
skin  ||| S:945 E:950 ||| NN
exhibited  ||| S:950 E:960 ||| NN
higher  ||| S:960 E:967 ||| RBR
C-C  ||| S:967 E:971 ||| JJ
chemokine  ||| S:971 E:981 ||| JJ
receptor  ||| S:981 E:990 ||| NN
( ||| S:990 E:991 ||| -LRB-
CCR ||| S:991 E:994 ||| NNP
) ||| S:994 E:995 ||| -RRB-
5  ||| S:995 E:997 ||| CD
expression ||| S:997 E:1007 ||| NN
,  ||| S:1007 E:1009 ||| ,
and  ||| S:1009 E:1013 ||| CC
the  ||| S:1013 E:1017 ||| DT
amount  ||| S:1017 E:1024 ||| NN
of  ||| S:1024 E:1027 ||| IN
C-C  ||| S:1027 E:1031 ||| JJ
chemokine  ||| S:1031 E:1041 ||| JJ
ligand  ||| S:1041 E:1048 ||| NNS
( ||| S:1048 E:1049 ||| -LRB-
CCL ||| S:1049 E:1052 ||| NNP
) ||| S:1052 E:1053 ||| -RRB-
5 ||| S:1053 E:1054 ||| CD
,  ||| S:1054 E:1056 ||| ,
a  ||| S:1056 E:1058 ||| DT
ligand  ||| S:1058 E:1065 ||| NN
for  ||| S:1065 E:1069 ||| IN
CCR5 ||| S:1069 E:1073 ||| NNP
,  ||| S:1073 E:1075 ||| ,
was  ||| S:1075 E:1079 ||| VBD
increased  ||| S:1079 E:1089 ||| VBN
in  ||| S:1089 E:1092 ||| IN
capillary  ||| S:1092 E:1102 ||| JJ
veins  ||| S:1102 E:1108 ||| NN
of  ||| S:1108 E:1111 ||| IN
psoriasis  ||| S:1111 E:1121 ||| JJ
plaques ||| S:1121 E:1128 ||| NN
.  ||| S:1128 E:1130 ||| .
CCR5+  ||| S:1130 E:1136 ||| NNP
iNKT-cell  ||| S:1136 E:1146 ||| JJ
numbers  ||| S:1146 E:1154 ||| NNS
significantly  ||| S:1154 E:1168 ||| RB
correlated  ||| S:1168 E:1179 ||| VBN
with  ||| S:1179 E:1184 ||| IN
the  ||| S:1184 E:1188 ||| DT
number  ||| S:1188 E:1195 ||| NN
of  ||| S:1195 E:1198 ||| IN
capillary  ||| S:1198 E:1208 ||| FW
vein  ||| S:1208 E:1213 ||| FW
endothelial  ||| S:1213 E:1225 ||| FW
cells  ||| S:1225 E:1231 ||| FW
expressing  ||| S:1231 E:1242 ||| FW
CCL5  ||| S:1242 E:1247 ||| FW
in  ||| S:1247 E:1250 ||| FW
PV ||| S:1250 E:1252 ||| FW
.  ||| S:1252 E:1254 ||| .
Furthermore ||| S:1254 E:1265 ||| RB
,  ||| S:1265 E:1267 ||| ,
the  ||| S:1267 E:1271 ||| DT
number  ||| S:1271 E:1278 ||| NN
of  ||| S:1278 E:1281 ||| IN
CCL5+  ||| S:1281 E:1287 ||| CD
capillary  ||| S:1287 E:1297 ||| NNS
veins  ||| S:1297 E:1303 ||| VBP
correlated  ||| S:1303 E:1314 ||| VBN
with  ||| S:1314 E:1319 ||| IN
the  ||| S:1319 E:1323 ||| DT
maximum  ||| S:1323 E:1331 ||| JJ
rete  ||| S:1331 E:1336 ||| JJ
ridge  ||| S:1336 E:1342 ||| JJ
length ||| S:1342 E:1348 ||| NN
.  ||| S:1348 E:1350 ||| .
IFN-γ ||| S:1350 E:1355 ||| NNP
/ ||| S:1355 E:1356 ||| NNP
CCR5  ||| S:1356 E:1361 ||| NNP
expression  ||| S:1361 E:1372 ||| NN
in  ||| S:1372 E:1375 ||| IN
iNKT  ||| S:1375 E:1380 ||| JJ
cells  ||| S:1380 E:1386 ||| NNS
and  ||| S:1386 E:1390 ||| CC
CCL5  ||| S:1390 E:1395 ||| CD
expression  ||| S:1395 E:1406 ||| NN
in  ||| S:1406 E:1409 ||| IN
vessels  ||| S:1409 E:1417 ||| NNS
of  ||| S:1417 E:1420 ||| IN
dermal  ||| S:1420 E:1427 ||| JJ
papillae  ||| S:1427 E:1436 ||| JJ
correlate  ||| S:1436 E:1446 ||| NN
with  ||| S:1446 E:1451 ||| IN
the  ||| S:1451 E:1455 ||| DT
development  ||| S:1455 E:1467 ||| NN
of  ||| S:1467 E:1470 ||| IN
psoriasiform  ||| S:1470 E:1483 ||| JJ
hyperplasia  ||| S:1483 E:1495 ||| NN
and  ||| S:1495 E:1499 ||| CC
microabscess ||| S:1499 E:1511 ||| NN
.  ||| S:1511 E:1513 ||| .
We  ||| S:1513 E:1516 ||| PRP
propose  ||| S:1516 E:1524 ||| VBP
that  ||| S:1524 E:1529 ||| IN
these  ||| S:1529 E:1535 ||| DT
iNKT  ||| S:1535 E:1540 ||| JJ
cells  ||| S:1540 E:1546 ||| NNS
may  ||| S:1546 E:1550 ||| MD
become  ||| S:1550 E:1557 ||| VB
useful  ||| S:1557 E:1564 ||| JJ
targets  ||| S:1564 E:1572 ||| NNS
for  ||| S:1572 E:1576 ||| IN
development  ||| S:1576 E:1588 ||| NN
of  ||| S:1588 E:1591 ||| IN
novel  ||| S:1591 E:1597 ||| JJ
therapeutic  ||| S:1597 E:1609 ||| JJ
approaches  ||| S:1609 E:1620 ||| NNS
to  ||| S:1620 E:1623 ||| TO
PV ||| S:1623 E:1625 ||| NNP
.  ||| S:1625 E:1627 ||| .
